






















Defects in energy metabolism, and, more specifically, 
mitochondrial function are intimately linked to the 
general decline in physiological functions during ageing 
[1]. While generally thought to be a consequence of 
random damage, the hypothesis that ageing should also 
be considered a metabolic state is gaining importance, 
as defective energy metabolism and DNA damage seem 
intimately intertwined. Indeed, a flurry of recent reports 
illustrates how DNA damage influences metabolic 
homeostasis by affecting mitochondrial function. A nice 
example of such a relationship was provided by the 
demonstration that dysfunction of telomere maintenance 
could impact on mitochondrial function [2]. The DNA 
damage induced by deficient telomere capping would 
decrease the activity of PGC-1a, a master transcriptional 
regulator of mitochondrial biogenesis, via a pathway 
that involved p53 activation. 
 
Recent observations from our lab [3,4] can complement 
the observations from Sahin et al and introduce a 
matching mechanism by which DNA-damage can 
influence mitochondrial biogenesis. This new pathway 
involves the interplay between two enzymes, i.e. the 
Poly(ADP-ribose) polymerases (PARPs) and the 
sirtuins. Both enzyme families are strongly conserved in 
eukaryotes and share the particularity of using NAD
+ as 
a cosubstrate, which is converted into nicotinamide 
(NAM) by the respective enzymatic activities [5]. 
PARP activity is mainly attributed to PARP-1, a 


























bind to various DNA structures and nucleosomes, and 
has important roles in DNA repair, chromosome 
stability and transcriptional regulation (for review, see 
[6]). The reaction catalyzed by PARP-1 uses NAD
+ to 
form polymers of ADP-ribose units onto acceptor 
proteins, cleaving off NAM. Cellular poly(ADP-ribose) 
(PAR) formation is dramatically stimulated upon DNA 
damage, and, as a result, NAD
+ levels plummet when 
DNA is damaged [6,7]. While PARP-1 accounts for 
90% of PARP activity under genotoxic situations, a 
second enzyme, PARP-2 is responsible for the 
remaining 10% [8,9]. The role and activation of other 
PARP family members under such circumstances 
remains unexplored.  
 
SIRT1, the first mammalian member of the sirtuin 
family identified, is a NAD+-depedent deacetylase that 
regulates diverse aspects of global metabolism by 
regulating the acetylation status and activity of a 
number of metabolic enzymes and transcriptional 
regulators [10]. Notable amongst these substrates is 
PGC-1a. SIRT1-mediated deacetylation of PGC-1a 
enhances its capacity to coactivate transcription of 
nuclear encoded mitochondrial genes [11]. SIRT1 
activity can be controlled by the regulation of its 
expression, by some post-translational modifications 
and, interestingly, by NAD
+ levels [5]. The Km of 
SIRT1 for NAD
+ is around the physiological 
concentration range of NAD
+, implying that in diverse 
circumstances, NAD
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proposed to act as an intracellular NAD
+ sensor that 
translates changes of the metabolic/redox state of the 
cell into adaptive transcriptional responses [12]. 
Furthermore of relevance is that the breakdown product 
of both the SIRT1 and PARP reactions, NAM, is an 
allosteric inhibitor of SIRT1 activity [13].  
 
The use of NAD
+ as a common cosubstrate has in the 
past led to propose a possible interrelationship between 
PARP and SIRT1 activities [14]. In two recent reports, 
we have established how this interrelationship has 
strong metabolic implications [3,4]. The deletion of 
either the PARP-1 or PARP-2 gene in mice enhances 
SIRT1 activity, which leads to a higher mitochondrial 
content, ability to oxidize fatty acids, ultimately 
culminating in the prevention against diet-induced 
obesity. Interestingly, PARP-1 and PARP-2 do so via 
very different mechanisms. The deletion of the PARP-1 
gene or the inhibition of PARP-1 activity boosts cellular 
NAD
+ content [3]. This effect on NAD
+ is not 
immediate, probably because PARP-1 activity is very 
low in cells/tissues in basal conditions, and it requires a 
protracted inhibition of PARP-1 to promote significant 
effects on NAD
+ accumulation. This enhanced NAD
+ 
content then activates SIRT1, leading to the 
deacetylation of key targets that induce mitochondrial 
biogenesis [3]. In contrast to NAD+ levels, NAM levels 
were not affected by PARP-1 deletion [3]. Conversely, 


























to H2O2, PARP-1 is activated and SIRT1 activity is 
robustly reduced, as PARP-1 activation limits NAD
+ 
bioavailability [3,7,15]. Treatment with PARP 
inhibitors in these circumstances allows the cell to 
maintain NAD
+ levels and SIRT1 activity [3]. 
Collectively with the fact that SIRT1 is not a substrate 
for and regulated by PARylation [3], these observations 
indicate that PARP-1 is a gatekeeper for SIRT1 activity 
by limiting NAD
+ availability.  
 
The case of PARP-2, however, is different. In line with 
its relatively minor role in global PARP activity [8,9], 
the reduction of PARP-2 levels does not influence 
NAD
+ levels in the cellular models [4]. Surprisingly, 
and similar to PARP-1, a reduction of PARP-2 levels 
were nevertheless also linked to SIRT1 activation [4]. 
This increase in SIRT1 activity, rather than being the 
consequence of a modulation of NAD
+ levels, was 
attributed to a higher expression level of SIRT1 [4]. In 
fact, PARP-2 binds directly to the SIRT1 promoter and 
represses its transcription [4]. Via this way, PARP-2 
gene deletion induced SIRT1 levels in all tissues and 
cell models tested, subsequently promoting 
mitochondrial biogenesis, enhancing the ability to 
oxidize fat and preventing against the onset of diet-
induced obesity [4]. Therefore PARP activation 
influences SIRT1 activity through two different means, 
i.e by limiting NAD
+ availability (PARP-1) and by 
regulating SIRT1 expression at the transcriptional level 
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DNA damage influences mitochondrial function and 
global metabolism. The binding of PARP-1 to DNA 
strand breaks and its subsequent catalytic activation 
might limit SIRT1 activity and, therefore, impede the 
correct maintenance of mitochondrial homeostasis. This 
relationship between PARPs and SIRT1 might not only 
affect metabolic control but also impact on aging. In 
fact, in lower eukaryotes, SIRT1 activity influences 
longevity and has been proposed to be a mediator of the 
effects of calorie restriction on lifespan extension [16]. 
Future research will have to establish whether PARP 
deletion/inhibition might alter lifespan by enhancing 
SIRT1 activity. One common criticism on this 
hypothesis is that reduced PARP activity might 
compromise DNA repair and maintenance. Therefore, a 
protracted decrease in PARP activity might be 
detrimental for proper cellular and organismal survival. 
While this is a fair hypothesis, it is also true that PARP-
1 or PARP-2 deficient mice do not show signs of 
enhanced DNA damage [17,18]. Such a phenotype only 
becomes evident when these mice are exposed to 
ionizing irradiation or chemically-induced genotoxic 
stress [18,19]. Interestingly, the simultaneous knock.out 
of both PARP-1 and PARP-2 results in embryonic 
lethality, indicating that PARP-1 and PARP-2 can 
compensate to a certain extent the key functions of each 
other in basal genomic maintenance and developmental 
processes [19]. 
 
A role for PARPs on longevity had been already 
postulated almost two decades ago, when experiments 
in permeabilized mononuclear leukocytes of 13 
different species revealed a positive correlation between 
maximal PARylation capacity and longevity [20]. 
PARylation capacity was not the consequence of higher 
PARP-1 enzyme content, but attributed to intrinsic 
differences in PARP activity [20]. Additionally, it was 
observed that PARP activity declined in aging 
mononuclear leukocytes [20,21]. These premises led to 
the speculation that enhanced PARP activity would 
allow longevity [22], which is diametrically opposite to 
the speculation derived from our studies [3,4]. How 
might this discrepancy be explained? First of all, it must 
be noted that the studies on PARP activity and 
longevity do not enable to establish a cause-effect 
relationship. Indeed, recent gain of function studies in 
mice which overexpress an additional copy of the 
human PARP-1 gene (hPARP-1 mice), demonstrated 
that increased PARP-1 gene dosage actually led to a 
premature occurrence of age-related diseases [23]. 
Many inflammation-related pathologies, such as 
glomerulopathy, nephritis, hepatitis, myocarditis/cardiac 
fibrosis, pneumonitis, and dermatitis, that naturally 
occur in old wild type mice develop in hPARP-1 mice 
at younger ages and with higher frequency and severity, 
leading to a reduced median lifespan [23]. This suggests 
that the higher PARP-1 activity in leukocytes from long 
lived individuals is rather a consequence but not the 
cause of longevity. Furthermore, it is difficult to 
evaluate whether the higher PARP-1 activity observed 
in the original experiments in leukocytes can be 
extrapolated to other cell types and tissues, including 
slowly dividing differentiated tissues.   
 
Our results obtained in the PARP-1 and PARP-2 knock-
out mice would also predict that higher PARP-1 gene 
dosage would compromise metabolic fitness. In line 
with the predictions from our studies, mice 
overexpressing hPARP-1 were heavier than their wild-
type littermates [23], an effect which was at least in part 
caused by increased fat mass and which was 
accompanied by glucose intolerance. These results 
consolidate our findings indicating that low PARP 
activity enhances metabolic fitness, prevents 
inflammation-related diseases and, potentially, extends 
health/lifespan. It will be, however, necessary to 
perform health/lifespan studies in organisms with 
chronically reduced PARP activity in order to 
rigorously test this hypothesis. This will not be an easy 
task, as some eukaryotes only have one PARP homolog 
and its deletion is lethal [24]. Similarly, in other 
organisms PARP homologs are dispensable for life, but 
their role in genomic maintenance might be different 
from that of the mammalian PARPs [25]. In addition, it 
will be interesting to understand to which extent sirtuins 
and/or NAD
+ homeostasis will be key to explain the 
possible relationship between PARPs and longevity. In 
this latter regard, it is notable that PARP deletion on 
mice has different, even opposite effects, depending on 
the mouse strain used [3,18,26,27]. This might 
underscore strain-dependent differences in NAD
+ 
metabolism, which requires future investigation. Indeed, 
C57Bl/6J, the most widely used mouse strain is 
defective for nicotinamide nucleotide transhydrogenase 
(Nnt) [28,29], prompting a higher susceptibility to 
develop defects in insulin secretion and altered glucose 
homeostasis. Nnt is a inner mitochondrial membrane 
protein that catalyzes the interconversion of NADH and 
NADPH in the mitochondrial matrix. The consequences 
that Nnt deficiency might really have on NAD
+ 
homeostasis are, however, not clear [5]. Furthermore, 
the fact that reducing PARP-1 activity with different 
genetic and pharmacological strategies in diverse 
cellular models faithfully recapitulates the effects 
observed in vivo clearly argues that the phenotype in 
the C57Bl/6J is genuine and not consequent to Nnt 
deficiency, and consolidates previous observations 
indicating that the Sv129 mouse strain is not optimal to 
evaluate metabolic disease phenotypes [30,31]. Finally, 
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which PARP activity might be balancing metabolism 
and genomic maintenance.  
 
Despite these novel and tantalizing findings, the many 
remaining open questions clearly illustrate that, half a 
century after their initial discovery [32], PARPs still 
have many aces up their sleeves. The quest to uncover 
the integral picture of PARP biology will warrant future 
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